Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Allogene Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
ALLO
Nasdaq
2836
www.allogene.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Allogene Therapeutics, Inc.
Allogene's Q3 Loss Narrower Than Expected, Sales Nil
- Nov 8th, 2024 3:15 pm
Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlights: Financial Resilience Amidst ...
- Nov 8th, 2024 11:07 am
Allogene Therapeutics: Q3 Earnings Snapshot
- Nov 7th, 2024 9:11 pm
Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update
- Nov 7th, 2024 9:02 pm
CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up
- Nov 7th, 2024 3:29 pm
Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS
- Nov 7th, 2024 3:00 pm
Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting
- Nov 5th, 2024 2:10 pm
Allogene Therapeutics Announces Participation in November Investor Conferences
- Nov 4th, 2024 1:30 pm
Earnings Preview: ANI Pharmaceuticals (ANIP) Q3 Earnings Expected to Decline
- Nov 1st, 2024 2:00 pm
Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know
- Oct 31st, 2024 2:01 pm
Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update
- Oct 30th, 2024 12:30 pm
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
- Oct 29th, 2024 12:43 pm
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
- Oct 29th, 2024 12:30 pm
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
- Oct 22nd, 2024 8:05 pm
Allogene Therapeutics, Inc. (ALLO): Among the Rising Penny Stocks to Invest In Now
- Oct 3rd, 2024 11:19 am
Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference
- Sep 30th, 2024 12:30 pm
Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence
- Sep 26th, 2024 12:30 pm
IGM Biosciences (IGMS) Surges 11.6%: Is This an Indication of Further Gains?
- Sep 18th, 2024 1:33 pm
Allogene Therapeutics, Inc. (ALLO): Short Seller Sentiment is Bearish on This Cancer Stock
- Sep 14th, 2024 9:39 pm
Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?
- Sep 6th, 2024 3:31 pm
Scroll